Cargando…

COMA: efficient structure-constrained molecular generation using contractive and margin losses

BACKGROUND: Structure-constrained molecular generation is a promising approach to drug discovery. The goal of structure-constrained molecular generation is to produce a novel molecule that is similar to a given source molecule (e.g. hit molecules) but has enhanced chemical properties (for lead optim...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jonghwan, Seo, Sangmin, Park, Sanghyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850577/
https://www.ncbi.nlm.nih.gov/pubmed/36658602
http://dx.doi.org/10.1186/s13321-023-00679-y
Descripción
Sumario:BACKGROUND: Structure-constrained molecular generation is a promising approach to drug discovery. The goal of structure-constrained molecular generation is to produce a novel molecule that is similar to a given source molecule (e.g. hit molecules) but has enhanced chemical properties (for lead optimization). Many structure-constrained molecular generation models with superior performance in improving chemical properties have been proposed; however, they still have difficulty producing many novel molecules that satisfy both the high structural similarities to each source molecule and improved molecular properties. METHODS: We propose a structure-constrained molecular generation model that utilizes contractive and margin loss terms to simultaneously achieve property improvement and high structural similarity. The proposed model has two training phases; a generator first learns molecular representation vectors using metric learning with contractive and margin losses and then explores optimized molecular structure for target property improvement via reinforcement learning. RESULTS: We demonstrate the superiority of our proposed method by comparing it with various state-of-the-art baselines and through ablation studies. Furthermore, we demonstrate the use of our method in drug discovery using an example of sorafenib-like molecular generation in patients with drug resistance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13321-023-00679-y.